New trial aims to stop cancer from accelerating on immunotherapy alone
NCT ID NCT07274384
First seen Jan 07, 2026 · Last updated May 10, 2026 · Updated 23 times
Summary
This study is for people with advanced non-small cell lung cancer that has a high level of a protein called PD-L1. Some patients with a specific blood marker are at risk of their tumors growing faster when treated with immunotherapy alone. The trial will compare standard immunotherapy (cemiplimab) versus immunotherapy plus chemotherapy to see if the combination can prevent this dangerous rapid growth. About 74 participants will be randomly assigned to one of the two treatment groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.